Merck's Keytruda picks up a trifecta with FDA approval to treat rare tumor type
admin 23rd May 2017 Uncategorised 0Talk about going on a roll. Merck’s Keytruda nabbed its third FDA approval in two weeks on Tuesday, becoming the first checkpoint inhibitor to pick up an approval to treat microsatellite instability-high cancer, a rare tumor type identified with genetic testing.
More: Merck's Keytruda picks up a trifecta with FDA approval to treat rare tumor type
Source: fierce